To provide synthesized evidence on the association between sarcopenia and risk of mortality, recurrence and postoperative complications in patients with bladder cancer and undergoing radical cystectomy (RC).
Methods
Only studies with observational design that investigated the association between sarcopenia and outcomes of interest among patients with bladder cancer undergoing RC were included. The outcomes of interest were mortality, recurrence, and postoperative complications. The systematic search was conducted using three large databases, that is, PubMed, EMBASE, and Scopus. A random effects model was used for the analysis and pooled effect sizes were reported as odds ratio (OR) or hazards ratio (HR) along with 95% confidence intervals (CIs).
Results
A total of 21 studies with 4997 patients were included. Compared to non-sarcopenic subjects, those with sarcopenia had increased risk of all-cause mortality (HR 1.45, 95% CI: 1.32, 1.61), cancer-specific mortality (HR 1.74, 95% CI: 1.49, 2.03) and a lower recurrence free survival (HR 1.84, 95% CI: 1.30, 2.62). Patients with sarcopenia also had higher risk of developing complications within 90 days postoperatively (OR 1.77, 95% CI: 1.23, 2.55).
Conclusion
Sarcopenia among patients with bladder cancer and managed using RC is associated with adverse survival outcomes and an increased risk of postoperative complications.
SaginalaKBarsoukAAluruJS, et al.Epidemiology of bladder cancer. Med Sci (Basel)2020; 8: 15.
2.
BrayFFerlayJSoerjomataramI, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018; 68: 394–424.
3.
DobruchJOszczudłowskiM. Bladder cancer: current challenges and future directions. Medicina (Kaunas)2021; 57: 749.
4.
Nik Ab KadirMNHaironSMYaacobNM, et al.Prognostic factors for bladder cancer patients in Malaysia: a population-based study. Int J Environ Res Public Health2022; 19: 3029.
5.
KucukUPalaEECakırE, et al.Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder. Cent European J Urol2015; 68: 30–36.
6.
ZhangLWuBZhaZ, et al.Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. BMC Cancer2019; 19: 716.
7.
AuPC-MLiH-LLeeGK-Y, et al.Sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia2021; 7: S28–S33.
8.
FronteraWROchalaJ. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int2015; 96: 183–195.
9.
DollyADumasJ-FServaisS. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?J Cachexia Sarcopenia Muscle2020; 11: 1413–1428.
10.
Cruz-JentoftAJBahatGBauerJ, et al.Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing2019; 48: 16–31.
11.
Meza-ValderramaDMarcoEDávalos-YeroviV, et al.Sarcopenia, malnutrition, and cachexia: adapting definitions and terminology of nutritional disorders in older people with cancer. Nutrients2021; 13: 761.
12.
HuangD-DWangS-LZhuangC-L, et al.Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis2015; 17: O256–O264.
13.
RierHNKharagjitsingHvan RosmalenJ, et al.Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma. Leuk Lymphoma2020; 61: 1618–1626.
14.
KatsuiKOgataTSugiyamaS, et al.Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. Sci Rep2021; 11: 11882.
15.
DalyLENí BhuachallaÉBPowerDG, et al.Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle2018; 9: 315–325.
16.
IbiliborCPsutkaSPHerreraJ, et al.The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: a systematic review and meta-analysis. Arab J Urol2021; 19: 98–103.
EggerMDavey SmithGSchneiderM, et al.Bias in meta-analysis detected by a simple, graphical test. Br Med J1997; 315: 629–634.
19.
WellGSheaBO’ConnellD, et al.The Newcastle-Ottawa (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa: Ottawa Hospital Research Institute. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 5 January 2023).
20.
YingTBorrelliPEdenbrandtL, et al.Automated artificial intelligence-based analysis of skeletal muscle volume predicts overall survival after cystectomy for urinary bladder cancer. Eur Radiol Exp2021; 5: 50.
21.
SuginoYSasakiTKatoM, et al.Prognostic effect of preoperative psoas muscle Hounsfield unit at radical cystectomy for bladder cancer. Cancers (Basel)2021; 13: 5629.
22.
MaoWMaBWangK, et al.Sarcopenia predicts prognosis of bladder cancer patients after radical cystectomy: a study based on the Chinese population. Clin Transl Med2020; 10: e105.
23.
WangKGuYNiJ, et al.Combination of total psoas index and albumin–globulin score for the prognosis prediction of bladder cancer patients after radical cystectomy: a population-based study. Front Oncol2021; 11: 724536.
24.
FraisseGRenardYLebacleC, et al.La sarcopénie est-elle un facteur de morbi-mortalité dans le traitement des tumeurs localisées de la vessie infiltrant le muscle?Progrès Urol2019; 30: 41–50.
25.
YamashitaSIguchiTKoikeH, et al.Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer. Int J Urol2021; 28: 757–762.
26.
LyonTDFrankITakahashiN, et al.Sarcopenia and response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clin Genitourin Cancer2019; 17: 216–222.e5.
27.
Stangl-KremserJAhmadiHDerstineB, et al.Psoas muscle mass can predict postsurgical outcomes in patients who undergo radical cystectomy and urinary diversion reconstruction. Urology2021; 158: 142–149.
28.
HaY-SKimSWKwonTG, et al.Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer. Int Braz J Urol2019; 45: 686–694.
29.
PsutkaSPBoorjianSAMoynaghMR, et al.Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol2015; 193: 1507–1513.
30.
HarrazAOsmanYFakhreldinI, et al.Mp67-01 sarcopenia as a predictor of cancer-specific and overall survival after radical cystectomy: is there a gender influence?J Urol2015; 193: e849–e850.
31.
HirasawaYNakashimaJYunaiyamaD, et al.Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol2016; 23: 1048–1054.
32.
MiyakeMMorizawaYHoriS, et al.Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer2017; 17: 237.
33.
MayrRGierthMZemanF, et al.Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle2018; 9: 505–513.
34.
SmithABDealAMYuH, et al.Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol2014; 191: 1714–1720.
35.
MayrRFritscheH-MZemanF, et al.Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer. World J Urol2018; 36: 1201–1207.
36.
Saitoh-MaedaYKawaharaTMiyoshiY, et al.A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. BMC Urol2017; 17: 87.
37.
GaoJShiYZhouD, et al.Sarcopenia as an independent predictor for venous thromboembolism events in bladder cancer patients undergoing radical cystectomy. Support Care Cancer2022; 30: 1191–1198.
38.
EngelmannSUPicklCHaasM, et al.Body composition of patients undergoing radical cystectomy for bladder cancer: sarcopenia, low psoas muscle Index, and myosteatosis are independent risk factors for mortality. Cancers (Basel)2023; 15: 1778.
39.
OliverJVemanaGVetterJ, et al.1626 Sarcopenia predicts post-operative complications and length of stay following radical cystectomy. J Urol2013; 189: e668–e669.
40.
WanFZhuYGuC, et al.Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer. World J Surg Oncol2014; 12: 14.
41.
AhmadiHMontieJEWeizerAZ, et al.Patient psoas muscle mass as a predictor of complications and survival after radical cystectomy. Curr Urol Rep2015; 16: 79.
42.
BellosTCTzelvesLIManolitsisIS, et al.Sarcopenia in urinary bladder cancer: definition, prevalence and prognostic value in survival. Maedica (Bucur)2022; 17: 427–435.
43.
HuXDouW-CShaoY-X, et al.The prognostic value of sarcopenia in patients with surgically treated urothelial carcinoma: a systematic review and meta-analysis. Eur J Surg Oncol2019; 45: 747–754.
44.
KostakopoulosNAKarakousisND. Frailty assessment and postoperative complications in urologic oncology operations. J Frailty Sarcopenia Falls2020; 5: 57–61.
45.
SuskindAMWalterLCJinC, et al.Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU Int2016; 117: 836–842.
46.
NiuXZhuZBaoJ. Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta-analysis. Cancer Cell Int2021; 21: 126.
47.
QiFZhouXWangY, et al.Pre-treatment prognostic nutritional index may serve as a potential biomarker in urinary cancers: a systematic review and meta-analysis. Cancer Cell Int2018; 18: 207.
48.
MoriKMiuraNMostafaeiH, et al.Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. Int J Clin Oncol2020; 25: 1459–1474.
49.
QiFXuYZhengY, et al.Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis. Ann Transl Med2019; 7: 531–531.
50.
Ignacio de UlíbarriJGonzález-MadroñoAde VillarNGP, et al.CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp2005; 20: 38–45.
51.
NiuXZhuZBaoJ. Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta-analysis. Cancer Cell Int2021; 21: 126.
52.
NozoeTNinomiyaMMaedaT, et al.Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today2010; 40: 440–443.
53.
de Ulíbarri PérezJIFernándezGRodríguez SalvanésF, et al.Nutritional screening; control of clinical undernutrition with analytical parameters. Nutr Hosp2014; 29: 797–811.
54.
CengizOKocerBSürmeliS, et al.Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma?Med Sci Monit2006; 12: CR240–CR247.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
